METHOD FOR DETERMINING CANCER PROGNOSIS
    4.
    发明申请
    METHOD FOR DETERMINING CANCER PROGNOSIS 审中-公开
    确定癌症预后的方法

    公开(公告)号:US20130316359A1

    公开(公告)日:2013-11-28

    申请号:US13982843

    申请日:2012-01-27

    Abstract: The present invention concerns an in vitro method for determining cancer prognosis for a patient suffering from early-stage or low-grade cancer, said method comprising measuring the expression level of ERRα in a biological sample comprising cancer cells. The invention further pertains to an in vitro method for determining bone metastases prognosis for a patient suffering from bone metastases comprising measuring the expression level of ERRα. Finally, the invention pertains to in vitro methods for selecting a patient suffering from cancer, and/or from cancer-derived metastasis, suitable to be treated with a preventive/aggressive therapy.

    Abstract translation: 本发明涉及用于确定患有早期或低级癌症的患者的癌症预后的体外方法,所述方法包括测量包含癌细胞的生物样品中的ERRalpha的表达水平。 本发明还涉及用于确定患有骨转移的患者的骨转移预后的体外方法,包括测量ERRalpha的表达水平。 最后,本发明涉及用于选择患有癌症和/或癌症转移的患者的体外方法,其适于用预防/侵略性治疗来治疗。

    Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases
    5.
    发明申请
    Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases 审中-公开
    用于治疗骨密度相关疾病的方法和药物组合物

    公开(公告)号:US20130195863A1

    公开(公告)日:2013-08-01

    申请号:US13823907

    申请日:2010-09-28

    Abstract: The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease.

    Abstract translation: 本发明涉及用于治疗骨密度相关疾病的方法和药物组合物。 更具体地,本发明涉及用于治疗受试者中与骨矿物质密度相关的疾病的方法中的ROBO1调节剂。 在一个具体实施方案中,ROBO1调节剂选自小有机分子,抗体,适体或多肽。 在另一个具体实施方案中,所述骨矿物质密度相关疾病选自由下列组成的组:颅内血肿发育不良综合征(GHDD),骨质疏松症,与假性胶质瘤相关的骨质疏松症,骨质疏松症和眼部色素沉着不全综合征,由内分泌功能障碍引起的骨质疏松症,成骨不全的骨质减少症,佩吉特氏病 骨髓炎,高钙血症,骨坏死,甲状旁腺功能亢进,溶骨转移,牙周炎,由固定引起的骨丢失和与选自恶病质,厌食症,脱发,类风湿性关节炎,牛皮癣关节炎,牛皮癣和炎症性肠病的疾病相关的骨质疏松症 。

    Patterns for a skeletal system
    6.
    发明申请
    Patterns for a skeletal system 审中-公开
    骨骼系统的模式

    公开(公告)号:US20070065803A1

    公开(公告)日:2007-03-22

    申请号:US10559819

    申请日:2004-06-11

    CPC classification number: G01N33/5017 A61L27/38 A61L27/46 G01N33/5088

    Abstract: The present invention relates to a bone system model comprising a mineralized matrix and osteoblasts, chararacterized in that the osteoblasts are deposited onto the matrix so as to form a layer at confluence and/or nodules, and the osteoclasts are deposited onto said layer and/or said nodules, and also to bone system models affected by various pathologies. The invention also covers the uses for carrying out screenings and tests for aggressiveness and for toxicity.

    Abstract translation: 本发明涉及包含矿化基质和成骨细胞的骨骼系统模型,其特征在于成骨细胞沉积在基质上以形成汇合和/或结节的层,并且破骨细胞沉积在所述层和/或 所述结节,以及受各种病理影响的骨系统模型。 本发明还涵盖用于进行筛选和检测侵袭性和毒性的用途。

Patent Agency Ranking